Is Singulair a Hormonal Drug?
Singulair is not a hormone drug. It is a leukotriene receptor antagonist, a type of Western medicine. It can generally inhibit airway constriction and spasm, reduce the pathological state of airway congestion and edema, and improve respiratory ventilation. Clinically, it is mainly used for bronchial asthma, allergic rhinitis, and asthmatic bronchitis. It is mainly used for the prevention and long-term treatment of asthma in children and adults over one year old, and can also be used to reduce symptoms caused by allergic rhinitis, including seasonal allergic rhinitis and perennial allergic rhinitis. In addition, the side effects of this drug are relatively rare during use, and most patients have good tolerance after use, usually without the need to terminate treatment.
The efficacy of oral administration of this product for the treatment of acute asthma attacks has not been determined, therefore, it should not be used to treat acute asthma attacks. Patients should be informed to prepare appropriate rescue medication. Although the inhaled glucocorticoid dose used concomitantly can be gradually reduced under the guidance of a doctor, this product should not be used to suddenly replace inhaled or oral glucocorticoids. There have been reports of neuropsychiatric events in patients taking this product (see adverse reactions). Since these events may also be caused by other factors, it cannot be confirmed whether they are related to this product. Doctors should discuss these adverse events with patients and/or caregivers. Patients and/or caregivers should be informed to notify the doctor if these situations occur. In rare cases, patients receiving anti-asthmatic drug treatment including leukotriene receptor antagonists may experience one or more of the following conditions: eosinophilia, vasculitic rash, worsening of lung symptoms, cardiac complications, and/or neuropathy (sometimes diagnosed as Churg-Strauss syndrome - a systemic eosinophilic vasculitis). These conditions are sometimes associated with the reduction or discontinuation of oral glucocorticoid treatment. Although the causality between these conditions and leukotriene receptor antagonists has not been determined, it is recommended to pay attention to patients taking Singulair and perform appropriate clinical monitoring.
